Treatment of progressive systemic sclerosis using factor XIII

Area of Science:

• Rheumatology
• Dermatology
• Hematology

Background:

• Progressive systemic sclerosis (PSS) is a debilitating autoimmune disease characterized by skin thickening and organ fibrosis.
• Current treatments for PSS have limited efficacy in addressing its diverse manifestations.
• Factor XIII, a key enzyme in the coagulation cascade, has potential therapeutic roles beyond hemostasis.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Factor XIII in patients with progressive systemic sclerosis.
• To compare Factor XIII treatment against a placebo in a randomized controlled setting.

Main Methods:

• A double-blind, randomized crossover trial involving 25 patients with PSS.
• Patients received intravenous Factor XIII or placebo for 3 weeks, followed by a 6-week washout period and crossover to the alternative treatment.
• Physician and patient assessments, along with a functional index for motor disability, were used for evaluation.

Main Results:

• Factor XIII significantly improved cutaneous manifestations of PSS compared to placebo.
• Patient- and physician-reported outcomes indicated superior efficacy of Factor XIII.
• A significant improvement in the motor function index was observed with Factor XIII treatment.
• Factor XIII exhibited good local and general tolerability, with no adverse events reported.

Conclusions:

• Factor XIII is an effective and well-tolerated treatment for the cutaneous and motor disability symptoms of progressive systemic sclerosis.
• Further research into Factor XIII's role in autoimmune fibrotic diseases is warranted.